Wednesday, January 09, 2008 5:59:13 PM
New User? Sign UpFinance Home -Help
Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesFinance Search New! Find Quotes Faster
You no longer need to remember symbols. Simply type in a company name or stock symbol for instant results.
Learn more... Close x 8988914
AP
Zix Expects to Meet Its 4Q Sales Outlook
Tuesday January 8, 11:08 am ET
Zix Expects to Meet Its 4th-Quarter Revenue Outlook on Strong Results From Businesses
DALLAS (AP) -- Zix Corp. said Tuesday it expects to meet its fourth-quarter sales forecast on strong results from its e-mail encryption and e-prescribing operations.
The company previously predicted quarterly revenue between $6.3 million and $6.8 million.
ADVERTISEMENT
Fourth-quarter e-mail encryption orders totaled $6.5 million, leading to a full-year order total of $24.2 million, which is 38 percent higher than the year-ago period. Zix said its PocketScript unit surpassed the high end of its fourth-quarter e-prescribing deployment outlook of 250 to 300 deployments with 327 deployments.
The company estimates 2007 revenue in a range of $23.4 million to $23.9 million, which would be a 28 percent to 30 percent increase from the prior year's results.
Zix also extended a distribution deal with Postini Inc. to package its e-mail encryption service with Postini services and offer them to the Google Inc. unit's customer base.
Shares of Zix gained 28 cents, or 7.5 percent, to $4 in morning trading. The stock has traded in a range of $1.16 to $6.24 over the past year.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM